Tiziana Life Sciences Ltd
Tiziana Life Sciences Ltd (TLSA): 2 pipeline candidates · 2 upcoming catalysts · ~10 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
9.6 months
D/E 1.87 · 0% dilution
Lead: Phase 2
2 candidates
2 upcoming, next in ~104d
N/A
A transparent, data-derived signal for Tiziana Life Sciences Ltdacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$141.3M
Cash
$3.7M
Quarterly Burn
$1.5M
Runway
9.6 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| foralumab | Phase 2 |
| foralumab tzls-401 | Phase 2 |
Upcoming Catalysts (2)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
29
Total value held
$847K
| Holder | Shares | Value |
|---|---|---|
| marshall wace, llp | 157,566 | $184K |
| geode capital management, llc | 78,204 | $91K |
| goldman sachs group inc | 75,660 | $89K |
| hsbc holdings plc | 62,437 | $76K |
| morgan stanley | 52,156 | $61K |
| ewa, llc | 45,948 | $54K |
| citadel advisors llc | 35,094 | $41K |
| susquehanna international group, llp | 31,967 | $37K |
| xtx topco ltd | 28,500 | $33K |
| point72 asset management, l.p. | 25,900 | $30K |
Showing top 10 of 29 institutional holders of Tiziana Life Sciences Ltd. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Tiziana Life Sciences Ltd's pipeline?
Tiziana Life Sciences Ltd (TLSA) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Tiziana Life Sciences Ltd's lead drug candidate?
Tiziana Life Sciences Ltd's most advanced tracked candidate is foralumab (Phase 2) for Secondary Progressive Multiple Sclerosis; Multiple System Atrophy.
What is Tiziana Life Sciences Ltd's next catalyst?
Tiziana Life Sciences Ltd's next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: intranasal foralumab" — expected September 30, 2026.
What is Tiziana Life Sciences Ltd's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Tiziana Life Sciences Ltd has approximately 9.6 months of cash runway.
What is Tiziana Life Sciences Ltd's market capitalization?
Tiziana Life Sciences Ltd's market capitalization is approximately $141.3M.
Get the full picture on Tiziana Life Sciences Ltd
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.